Vaxart Starts Recruitment In Mid-Stage COVID-19 Oral Vaccine Trial
Vaxart Inc (NASDAQ:VXRT) has begun recruiting subjects for its Phase 2 COVID-19 oral tablet vaccine clinical trial. Related: FDA Clears Vaxart’s Mid-Stage…
Vaxart Reports Has Begun Recruiting Subjects For Phase 2 COVID-19 Oral Tablet Vaccine Trial
Start of US Phase II of S-Only Vaccine Candidate Expected Later This Month
Ex-US Clinical Trials to Begin Later This Year with India Study
SOUTH SAN FRANCISCO, Calif., Oct. 6, 2021 /PRNewswire/ -- Vaxart, Inc.
What’s Going On With Vaxart’s Stock?
Vaxart Inc. (NASDAQ: VXRT) shares traded higher Tuesday after a study titled "A Phase 2 Trial With an Oral Tableted Covid-19 Vaccine" was posted to Clinicaltrials.gov. This may have inspired retail traders to buy the stock.
Vaxart closed up 4.89% at $7.30.
Vaxart Study Titled ‘A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine’ Posted To ClinicalTrials.Gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05067933
Vaxart Reports Has Formed Manufacturing, Quality Advisory Board
Vaxart, Inc. (NASDAQ:VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.
"We are very excited to be able to tap into the vast knowledge of this group of experts," said
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a technical pattern.
Vaxart was down 4.74% at $8.35 at last check Monday afternoon.
Unusual Options Activity Insight: Vaxart
Vaxart (NASDAQ:VXRT) shares experienced unusual options activity on Wednesday. The stock price moved down to $8.67 following the option alert.
Unusual Options Activity Insight: Vaxart
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved up to $10.11.
28 Stocks Moving in Friday’s Pre-Market Session
Gainers
Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of cryptocurrency mining assets.
Vaxart Q2 EPS $(0.13) Down From $(0.12) YoY, Sales $112.00K Down From $523.00K YoY
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.13) per share. This is a 8.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $112.00 thousand in sales this